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Latent Membrane Protein 1 (LMP1) is an EBV-transforming protein which is detected both in lymphoblastoid cell lines—
resulting from EBV-immortalization in vitro—and in undifferentiated nasopharyngeal carcinoma (NPC), an EBV-associated
malignancy of epithelial origin. To better define LMP1 subcellular targets, LMP1 distribution was analyzed in cellular
glycosphingolipid-rich complexes (GSL-complexes) derived from epithelial and lymphoid cells. These complexes are obtained
by extraction of glycosphingolipid-rich membrane domains (GSL-domains), which are clustering sites for heterotrimeric G-
proteins and G-protein-associated receptors. LMP1 concentration was enriched 50-fold in GSL-complexes extracted from
a NPC tumor line, C15. High concentrations of LMP1 were also observed in GSL-complexes derived from cultured lymphoid
and epithelial cells. These data suggest that association with GSL-domains is an important step in LMP1 trafficking and is
probably required for some aspects of its biological activity. q 1997 Academic Press
INTRODUCTION addition, LMP1 causes phenotypic changes, which,
sometimes, can be detected in fully transformed cells.
The Epstein–Barr virus (EBV) is involved in several hu-
Some of these changes occur in both lymphoid and epi-
man malignancies, including African Burkitt lymphoma,
thelial cells, for example induction of CD40, CD58, and
undifferentiated nasopharyngeal carcinoma (NPC), post-
protein A20 (Dawson et al., 1990; Hu et al., 1993; Miller
transplant lymphoma, and about half the cases of Hodgkin
et al., 1995). They are, at least partially, mediated by
lymphomas (Rickinson and Kieff, 1996). EBV efficiently im-
activation of NF-kB factors (Hammarskjold and Simurda,
mortalizes human primary B-cells in vitro. Experiments
1992; Mitchell and Sugden, 1995; Huen et al., 1995; Paine
based on EBV-recombinant technologies have identified
et al., 1995). However, in some cell lines such as BALB/
6 EBV latent proteins which are essential for B-lymphocyte
3T3, LMP1 causes transformation without inducing NF-
immortalization (Kieff et al., 1996). Five of these proteins
kB activity (Mitchell and Sugden, 1995). Recently there
are nuclear (including EBNA 1) and one is a membrane
has been work to identify LMP1 cellular partner proteins.
protein called latent membrane protein 1 (LMP1). LMP1
Several cDNAs coding for proteins with affinity for the C-
is one of the few EBV proteins consistently detected in
terminal domain have been cloned, using the yeast two-
EBV-associated malignancies (Fahraeus et al., 1988; Del-
hybrid screening system. One of these proteins, LAP1 or
sol et al., 1992). For example, it is detected in about 50% TRAF 3, is also a cytoplasmic partner protein for CD40
of invasive NPC and in a much higher percentage of prein- and the p80 TNF receptor (Mosialos et al., 1995).
vasive NPC, suggesting that LMP1 is involved in early LMP1 subcellular localization and trafficking have not
stages of oncogenesis (Fahraeus et al., 1988; Pathmana- been fully described. LMP1 has a rapid turn over. It is
than et al., 1995). rapidly transported to the plasma membrane and subse-
LMP1 is a 386-amino-acid integral membrane protein quently internalized and degraded, suggesting that it may
with a structure reminiscent of a truncated G-protein- function as a permanently activated membrane receptor
associated receptor. It has a short intracytoplasmic N- (Liebowitz et al., 1986; Martin and Sugden, 1991a). Newly
terminal domain (25 aa), 6 transmembrane domains, and synthesized LMP1 can be extracted with nonionic deter-
a long intracytoplasmic C-terminal domain (200 aa) gents but becomes detergent-insoluble when it matures
(Mann et al., 1985; Liebowitz et al., 1986). LMP1 trans- (Mann and Thorley-Lawson, 1987; Liebowitz et al., 1987;
forms murine fibroblasts and is tumorigenic in immortal- Martin and Sugden, 1991b). The insolubility of mature
ized nontumorigenic epithelial cell lines (Wang et al., LMP1 is thought to be due to its binding to cytoskeletal
1985; Baichwal and Sugden, 1987; Hu et al., 1993). In elements and immunocytochemistry has suggested that
LMP1 is associated to vimentin intermediate filaments
(Liebowitz et al., 1987). This is further supported by the1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 33-01-42-11-54-94. E-mail: pbusson@igr.fr. fact that LMP1 produced in the Daudi cell line, a Burkitt
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lymphoma cell line which lacks vimentin, remains almost
completely soluble in nonionic detergents. However,
LMP1 produced in Daudi cells retains both its biological
activity and its usual pattern of fluorescence with mem-
brane patches (Liebowitz and Kieff, 1989).
The aim of this study was to search for novel subcellu-
lar structures targeted by LMP1. Glycosphingolipid-rich
domains (GSL-domains) are potentially such structures
as they are clustering sites for molecules involved in
signal transduction, including heterotrimeric G-proteins,
G-protein-associated receptors, and nonreceptor tyro-
sine-kinases (Sargiacomo et al., 1993; Chun et al., 1994;
Gorodinski and Harris, 1995). GSL-domains are discrete
domains of the lipid bilayer with a high content of glycos-
phingolipids (GSL), sphingomyelin, and cholesterol and
a low content of phospholipids and glycerolipids
(Schroeder et al., 1994; Hanada et al., 1995). Initially iden-
tified in polarized epithelial cells, GSL-domains have sub-
sequently been observed in a wide variety of mammalian
cell lineages. They are present both in the plasma mem-
brane and the internal membrane network (Brown and
Rose, 1992; Kurzchalia et al., 1995). Due to their low
density and relative insolubility in nonionic detergents,
GSL-domains can be purified in the form of glycosphin-
golipid rich complexes (GSL-complexes) (regardless of
their morphology and cell localization). Most proteins
present in GSL-domains are preserved in GSL-com-
plexes (Sargiacomo et al., 1993; Chang et al., 1994; Fra
et al., 1994; Gorodinski and Harris, 1995). We first investi- FIG. 1. Summary of the cell fractionation procedure.
gated LMP1 content in GSL-complexes from a NPC tu-
mor line, C15, and subsequently extended our observa-
Lawson (Tufts University, Boston) (Mann et al., 1985) andtions to other types of EBV-carrying cells.
CS 1–4 which is a pool of 4 monoclonal antibodies di-
rected against different LMP1 epitopes (Dako, France)
MATERIALS AND METHODS (Rowe et al., 1987). The following antibodies were also
used: a monoclonal antibody directed against the integrinCell and tumor lines
b3 (Transduction Laboratories, Lexington, KY); an affinity-
C15 and C17 tumor lines were derived from NPC biop- purified polyclonal antibody against caveolin 1 (Trans-
sies and passaged in nude mice (Busson et al., 1988). duction Laboratories); and a monoclonal antibody
C15 cells consistently produced LMP1 which was unde- against vimentin (Amersham, France).
tectable in C17 cells used as controls (personal data).
EBV1 is a LCL immortalized by the EBV B95 strain (Nguer Purification of the GSL-complexes on a step-gradient
et al., 1992). Daudi LMP6 —kindly provided by F. Wang
The procedure used for fractionation of the GSL-com-(Harvard University, Boston)—is a subclone of the Daudi
plexes was based on modifications of the methods ofcell line stably transfected with the LMP1 B95 gene, un-
Sargiacomo et al. (1993), Fra et al. (1994), and Gorodinskyder the control of the human metallothionein promoter
and Harris (1995) (Fig. 1). It involved Triton X-100 extrac-and maintained by selection with mycophenolic acid
tion and flotation through a sucrose step gradient. This(pSV2gpt MTLM plasmid) (D. Wang et al., 1985; F. Wang
protocol had two important features: it was applicableet al., 1990). HL1 is a subclone of Hela cells also stably
to both tumor tissue and cultured cells with only minortransfected with the pSV2gpt MTLM plasmid; it has typi-
adaptations and it allowed the simultaneous analysis ofcal features of LMP1 expression: increased cell volume,
proteins and glycolipids.fibroblastic morphology, and elevated ICAM1 expression.
A 500-mg piece of tumor was minced and disrupted
in 3 ml MES-buffered saline (MBS) (25 mM MES, pH 6.5,Antibodies
150 mM NaCl) containing 1% Triton X-100 and 0.5 mM
Pefabloc (Pentapharm, Switzerland), at 47, using a coni-Two reagents were used to detect the LMP1 protein:
monoclonal antibody S12, kindly provided by D. Thorley- cal pestle-glass grinder. The lysate was further homoge-
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TABLE 1nized by 10 strokes in a tight fitting Dounce. A 100-ml
sample of the homogenate was retained (designated Protein Distribution (%) in Fractions from Various Tumor
TOT). The remainder was clarified by centrifugation at and Cell Lines
150 g for 1 min. The pellet was named D1. The clarified
Fractionshomogenate was made up to 4 ml in 1.2 M sucrose
MBS–Triton and placed in a SW41 ultracentrifuge tube.
Cell lines TOT D1 D2 d I40 I30
It was overlaid with 4.5 ml 0.9 M sucrose MBS buffer
(without Triton) and a third layer of 2.7 ml MBS (without C15 100 11.6 7 0.3 80 Negligible
EBV 1 100 2.7 26 2.2 65.2 2.7sucrose) and centrifuged at 180,000 g at 47, in a SW 41
Daudi-LMP6 100 6.3 10.7 0.5 77 4.4Beckman rotor, for 18 to 20 hr. The light Triton-insoluble
HL1 100 15.4 26.8 0.8 55 Negligiblematerial containing GSL-complexes was visible as an
opaque band 5 mm below the interface of the upper and
middle gradient layers. Refractive index measurements
The d fraction accounted for 0.3–2.2% of total protein.showed that the sucrose concentrations at this point was
The I30 fractions from EBV1 and Daudi cells were theusually 0.45 M (0.3–0.6 M). The band was harvested,
only I30 fractions to contain significant amounts of pro-diluted to a final volume of 3 ml in MBS, and centrifuged
teins; therefore, this fraction was not analyzed in the C15at 300,000 g at 47 for 60 min in a TLA 100.3 Beckman
and HL1 material.rotor. The resulting pellet was known as the ‘‘d fraction.’’
The amount of protein in the upper layer was always
Western blot analysisnegligible. The 30 and 40% sucrose layers were both
collected and called fractions I30 and I40. Finally a pellet At least two samples from each fraction were analyzed
of heavy Triton-insoluble material was retained and by Western blotting. One gel was run with a high protein
named fraction D2. The D1, d, and D2 pellets were solubi- load, about 50 mg, to obtain visible Ponceau staining of
lized in 10 vol of 6% SDS RIPA buffer (150 mM NaCl, 25 the corresponding membrane (Immobilon P; Millipore,
mM Tris, pH 7.4, 5 mM EDTA, 0.5% Na DOC, 0.5% NP- France). Another gel was run with a much smaller protein
40) for protein assay and Western blot analysis. The d load, 10 mg or less, to optimize LMP1 band resolution.
pellet was solubilized by pipetting. Solubilization of the The ECL system was used to visualize bound peroxi-
D1 and D2 pellets often required the use of disposable dase-conjugated secondary antibodies, as recom-
microtube pestles (Kontes, NJ) and/or sonication with a mended by the manufacturer (Amersham, France). Band
microtip probe. Aliquots of the total lysate and the I30 intensities were measured by laser densitometry using
and I40 fractions were diluted 10-fold and homogenized a Chromoscan III densitometer (Joyce Loebl, France),
in 6% SDS RIPA buffer and subjected to protein assay in the transmission mode. LMP1 concentration in each
and Western blot analysis. fraction was estimated from the band intensity per micro-
The fractionation of cultured cells required the follow- gram of protein loaded. Finally LMP1 enrichment was
ing modifications to the protocol. The extraction was per- determined as the ratio of LMP1 concentration in a given
formed on 108 floating cells or on attached cells from fraction to LMP1 concentration in the total homogenate.
eight 175-cm2 flasks. Cells were resuspended in 3 ml
MBS with Triton and Pefabloc and disrupted with three Glycosphingolipid analysis
15-sec pulses of the Polytron homogeneizer. The proce-
dure was thereafter identical to that described for tumor The fractions of the C15 tumor and the EBV1-cultured
cells described above were analyzed for GSL. The proto-tissue.
col described for protein analysis was used with the
following modifications. The initial amount of biologicalProtein assay and assessment of protein recovery
material was fourfold greater (2 g tumor or 4 1 108 cells).
At each step, 25% of the material was set apart for proteinProtein concentrations were assayed using the Bio-
Rad detergent compatible microassay system, against assay. The D1, d, and D2 pellets were dried and their
lipids extracted with chloroform/methanol. Lipid extrac-an albumin standard scale (Bio-Rad, France). Samples
were diluted to a final protein concentration of less than tion from the total homogenate and the I40 and I30 frac-
tions required pelleting of insoluble material by centrifu-2 mg/ml according to the manufacturer’s instructions.
In all our experiments, the total amount of proteins gation at 300,000 g at 47 for 60 min in a TL 100.3 rotor
(prior to this centrifugation, the I30 and I40 fractions wererecovered from the various fractions was very close to
that predicted from the protein concentration in the initial diluted fourfold in MBS buffer to decrease the sucrose
concentration).homogenate (Table 1). Most proteins were recovered in
the I40 liquid fraction (50 to 80%, depending on the cell The pellets were resuspended in approximately 10 vol
of chloroform/methanol (2/1) and sonicated for 30 mintype). The D1 and D2 pellets, containing high density
material, together accounted for 17–42% of total protein. in a Branson bath sonicator. The material insoluble in
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chloroform/methanol was pelleted by a 5-min centrifuga-
tion at 10,000 g and discarded. The chloroform/methanol
was evaporated under nitrogen and the lipid extract con-
centrated in a maximum volume of 50 ml of chloroform/
methanol (2:1). Lipid extracts were chromatographed on
an HTPLC plate (Si-HPF, J. T. Baker Chemicals, France)
along with standard GSL: CMH, Lac Cer, Gb3, and GM3
(5 mg each) (Sigma, France). GSL were visualized by
spraying with 0.5% orcinol in 10% H2S O4 and heating at
1207 for 10 min.
To estimate GSL concentration in each fraction, both
the sample and standard lanes were subjected to densi-
tometry scanning (using a Chromoscan III densitometer
in the reflection mode). The total amount of glycolipids
loaded in each sample lane was estimated according to
their densitometry values by comparison with the stan-
dards. GSL to protein ratios were calculated for each
fraction and results were expressed in micrograms of
glycolipid per milligrams of protein.
Assessment of Triton-soluble and -insoluble LMP1 in
EBV1 and Daudi I40 fractions
A sample of each fraction was dialyzed against 1%
Triton–MBS buffer to remove sucrose and centrifuged at
300,000 g to pellet Triton-insoluble material. After solubi-
lization of the pellets in 6% RIPA/SDS, equal amounts of
Triton-soluble (S) and insoluble (I) protein were subjected
to electrophoresis, blotted, and analyzed with the S12
anti-LMP1 antibody. Band intensities were measured by
laser densitometry.
RESULTS
LMP1 in GSL-complexes from the C15 tumor line
The GSL-complexes from the C15 and C17 (control)
tumor lines were fractionated, simultaneously. The LMP1
concentration was consistently high in the GSL-com- FIG. 2. Western blot analysis of the fractions obtained from the C15
and C17 NPC tumor lines. Samples of the C17 and C15 fractions wereplexes (d fraction). LMP1 was more than 50-fold enriched
separated on a 7.5% acrylamide gel. The C17 membrane was stainedin the d fraction (Fig. 2; Table 2). As the d fraction ac-
with the anti-LMP1 antibody CS1-4. The C15 membrane was stainedcounted for 0.3% of the C15 tumor proteins, the estimated
sequentially with anti-LMP1 (CS1-4), anti-vimentin, and anti-integrin b3
amount of LMP1 carried by the GSL-complexes was 15% antibodies. C15 (a), short exposure; C15 (b), long exposure. In both
(Tables 1 and 2). In contrast, LMP1 concentrations in the tumor cell extracts, the I30 fraction was not analyzed by Western blot-
ting (the amount of protein being negligible).D1, D2, and I40 fractions were smaller than in the total
homogenate.
The same membrane was reprobed with an anti-vi-
bution with that of another membrane protein not prefer-mentin antibody to investigate the distribution of vimentin
entially associated with GSL-complexes (Fra et al., 1994).in the C15 material (Fig. 2). No vimentin band was visible
Integrin b3 was mainly detected in the I40 fraction andin the total lysate; however, a significant amount of vi-
was usually absent in the d fraction.mentin was recovered selectively in the two high density
As most cellular proteins were present in the I40 fraction,pellets (D1 and D2), which were expected to contain
additional cellular structures associated with LMP1 couldcytoskeletal elements. Vimentin was not detectable in
have been overlooked by the step gradient analysis. There-the GSL-rich fraction. The presence of vimentin was con-
fore, the C15 Triton-insoluble elements were also analyzedfirmed in the C15 and C17 tumor lines by immunocyto-
on a continuous sucrose gradient. Interestingly, a singlechemistry (data not shown). The C15 fractions were then
probed with an anti-integrin b3 to compare LMP1 distri- LMP1 peak was recovered at a 0.45 M sucrose concentra-
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TABLE 2 LMP1 in the D1 fraction, which contained high density
Triton-insoluble material (Fig. 4). LMP1 solubility in DaudiQuantitative Analysis of C15 Fractions
cells and EBV1 cells was further compared. Triton-solu-
Proteins TOT D1 D2 d I40 ble and -insoluble elements contained in the I40 fraction
were partitioned (the I40 fraction contained the major
Relative concentration of LMP1, Vimentin, and Integrin b3 part of LMP1, although at a low concentration). The solu-
LMP1 (fold enrichment) 1 0.82 0.17 52 0.82 ble to insoluble LMP1 ratio was much higher in the Daudi
Vimentin 0 // // 0 0 than the EBV1 I40 fraction (0.8 and 0.2, respectively), as
Integrin b3 (fold 1 0.4 0.08 0 1.2 shown in Fig. 5.
enrichment)
In contrast to LMP1, vimentin was detected only in the
D1 and D2 fractions for EBV1 and HL1; it was completelyGlycolipid/protein ratio
undetectable in the Daudi fractions. Integrin b3 was mainly
Protein (mg) 2.9 9.5 10.5 0.5 5 found in the I40 fractions from all three cell types (Fig. 4).
Glycolipid (mg) 3.6 5.9 4.7 26.1 3.0
The distribution of caveolin 1 was investigated in the HL1Glycolipid/protein (mg/mg) 1.24 1.59 0.44 52.2 1.66
clone. Caveolin 1 is the prototype of a family of integral
membrane proteins which is frequently produced in epithe-
lial cells. It associates specifically with a morphologically
tion, corresponding to the density of the d fraction recov-
defined subset of GSL-domains called caveolae (Murata et
ered from the step sucrose gradient (data not shown). It
al., 1995; Schnitzer et al., 1995). Caveolin production and
had been assumed that the d fraction was highly enriched
caveolae formation is often suppressed or reduced in trans-
in GSL, on the basis of previous reports using similar frac-
formed cells (Koleske et al., 1995). However, a significant
tionation protocols. To confirm this assumption, lipid extrac-
amount of caveolin was found in the d fraction of wild-typetion and GSL analysis was performed on the various frac-
Hela and HL1 cells (Fig. 4). Although LMP1 and caveolintions obtained from the C15 tumor by thin layer chromatog-
1 were both highly concentrated in the d fraction of HL1raphy (TLC) (Fig. 3). The bands with maximal intensities
cells, immunocytochemistry with double color-immunofluo-were in the d fraction. Negatively charged GSL such as
rescence did not evidence colocalization of these two pro-monosialogangliosides GM1 and GM3 migrate at short dis-
teins (data not shown).tance of the origin and were poorly resolved in this experi-
Glycosphingolipid analysis was performed on the frac-ment because of the presence of impurities, especially su-
tions obtained from the EBV1 LCL (Fig. 6). Several bandscrose contaminants. In contrast, among neutral GSL, two
were detected in the total homogenate and in the D1doublet bands were easily identified, with the same mobility
fraction; however, the most intense bands were in the das CMH and Lac Cer. A very faint band comigrating with
fraction which had, as previously observed for C15, theGb3 was also visible. Regardless of their migration charac-
teristics, the ratio of glycosphingolipids to proteins was
much higher in the d fraction than in all other fractions
(Table 2).
LMP1 in GSL-complexes from other cell types
Three additional cell types were similarly investigated:
EBV1, a conventional LCL propagated in vitro, and two
clones transfected with the LMP1 gene, Daudi-LMP6 and
HL-1, derived from the Daudi and the Hela cell lines,
respectively. Among the fractions obtained from each cell
line, the GSL-rich fraction consistently had the highest
concentration of LMP1, although enrichment was not as
high as for the d fraction of C15 cells (Fig. 4 and Table
3). The same distribution of LMP1 was observed in EBV1
cells propagated as tumors in SCID mice, with a similar
enrichment in the d fraction (data not shown). The FIG. 3. Glycosphingolipid analysis of the fractions obtained from the
amount of LMP1 contained in the GSL-complexes was C15 tumor line. Lipid extracts obtained from the various fractions were
chromatographed with the GSL standards: CMH (glucosyl ceramide),much smaller in the Daudi-LMP6 clone than in other cell
Lac Cer (lactosyl ceramide), Gb3 (globotriaosylceramide), and GM3types (2.1 versus 15.6% for the EBV1 LCL). This difference
(monosialoganglioside GM3). The solvent system for TLC was chloro-was largely due to the small amount of protein recovered
form:methanol:water (50:40:10, v/v/v). For each lane, the GSL to protein
in this fraction; LMP1 was still more than fivefold en- ratio is presented in Table 2. The spots close to the origin of the
riched in the d fraction compared to the total homoge- chromatography for D2, d, and I40 fractions are due to sucrose contami-
nations.nate. In contrast to EBV1 cells, Daudi cells had no visible
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FIG. 4. Western-blot analysis of the fractions obtained from EBV1, Daudi-LMP6, and HL1 cells. For both EBV1 and Daudi-LMP6, two 7.5% gels
were run with either a large or a small protein load. Blotted membranes were stained sequentially with anti-LMP1 (S12) and anti-vimentin or anti-
integrin b3 antibodies. A residual LMP1 band is visible in the d fraction lane of EBV1 and Daudi membranes stained with the anti-vimentine antibody.
For HL1, one 7.5% and one 15% polyacrylamide gel were blotted onto 2 membranes stained sequentially with the following antibodies: anti-LMP1
(S12) and anti-integrin b3 antibodies (7.5% gel); anti-caveolin and vimentin (15% gel). The amount of protein was negligible in the I30 fraction which
was not investigated by Western blotting.
highest GSL/protein ratio. Doublets with the same mobil- caveolin-showed the distribution expected in these ex-
periments; (3) even when cells were fractionated in theity as CMH, LacCer, and Gb3 were visible.
absence of Triton X-100, high concentrations of LMP1
were recovered in the low density fraction, although withDISCUSSION
a relatively smaller yield (data not shown). Thus the high
recovery of LMP1 in GSL-complexes is likely to reflectLMP1 was found at a remarkably high concentration
its accumulation in GSL-domains in situ. Previous studiesin GSL-complexes from an NPC tumor line. This observa-
have shown that LMP1 becomes insoluble to nonioniction was extended to cultured cells expressing LMP1,
detergents when it matures. LMP1 present in GSL-com-both of lymphoid and epithelial origin. The results are
plexes might be a component of this insoluble pool. Thisunlikely to be an artefact due to cell homogeneization
does not exclude that a substantial amount of LMP1for several reasons: (1) the same pattern of LMP1 distri-
may associate with cytoskeletal elements, possibly withbution was found in different cell types, with homoge-
vimentin. Interestingly, a significant amount of LMP1 wasnates obtained from both cultured cells and tumor tissue;
(2) several different proteins-vimentin, integrin b3, and
TABLE 3
LMP1 Content in the d Fraction Obtained from Cultured Cells
Estimated fold-
Cell lines enrichment % LMP
EBV1 8.2 18
Daudi-LMP6 5.7 2.9
HL1a 8.3 6.6
FIG. 5. Assessment of Triton-soluble (S) and -insoluble (I) LMP1 in
Daudi and EBV1 I40 fractions (the soluble to insoluble LMP1 ratios area In the case of HL1, LMP1 enrichment in the d fraction was calcu-
lated by comparison with the I40 fraction. 0.8 and 0.2, respectively).
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of the LMP1 amino-terminal domain including the first
four transmembrane segments (only amino acids 129 to
386 are retained). D1-LMP1 does not form patches in
transfected cells, is nontransforming and has only very
limited effects on NF-kB induction (Huen et al., 1995).
Interestingly, D1-LMP1 produced in both epithelial and
lymphoid transfectants does not accumulate in GSL-com-
plexes (data not shown). This suggests that the LMP1
amino-terminal domain, which is not dispensable for cell
transformation and NF-kB induction, is important for the
recruitment of LMP1 in GSL-complexes. We hope to con-
firm this hypothesis by analysis of additional transfected
cell lines.
At first examination, the concept of LMP1 accumula-
tion in GSL-complexes from both epithelial and lymphoid
FIG. 6. Glycosphingolipid analysis of the fractions obtained from the
cells seems to be inconsistent with the fact that LMP1EBV1 cell line. GSL standards are the same as described in the legend
does not have the same pattern of immunofluorescenceof Fig. 3. For each lane the following GSL to protein ratios were obtained
(mg glycosphingolipid/mg protein): TOT (total homogenate), 0.44; D1, in both cell types. One or two large patches are often
0.56; D2, 0.03; d, 26; I40, 0.42 (for the calculation method, see Materials seen in lymphoid cells in contrast with multiple ponctu-
and Methods). In the I30 fraction, the GSL to protein ratio was similar ations in epithelial cells (Dawson et al., 1990 and per-
to that for I40 (data not shown).
sonal data). However, these differences may reflect dis-
tinct patterns of GSL-domain distributions in the plasma
membrane of both cell types. Lymphocytes and macro-recovered in high density fractions (D1 and D2) which
were enriched in vimentin. phages are unpolarized cells in a resting state but be-
come polarized upon activation. GSL-domains such asLMP1-enrichment was more marked in GSL-com-
plexes of NPC cells than lymphoid cells. However, this CD59-carrying complexes are involved in cell polariza-
tion and cluster in large patches (Van Den Berg et al.,was not due to a higher absolute level of LMP1 concen-
tration in GSL-complexes but, on the opposite, to the low 1995; Deckert et al., 1996). LMP1 carrying GSL-com-
plexes may undergo a similar process. In contrast, thereLMP1 concentration in the total extract of C15 cells (Figs.
2 and 4). Transfected Hela cells (HL1) which had a higher is no known process of cell polarization in NPC or trans-
fected Hela cells. It could be hypothesized that in epithe-LMP1 content than C15 cells also had a smaller level of
LMP1-enrichment in GSL-complexes. These observa- lial cells, LMP1-carrying complexes converge toward
multiple scattered foci which form the punctuations visi-tions suggest that LMP1 recruitment in GSL-domains is
more efficient in NPC cells or, alternatively, that LMP1 ble under fluorescence microscopy.
Further investigations are necessary to characterizeaccumulation in GSL-domains reaches a threshold of
saturation or cell toxicity in a context of intense LMP1 LMP1-containing GSL-complexes. It is clear that GSL-
domains in mammalian cells do not all have the sameproduction.
The consistent accumulation of LMP1 in GSL-com- structure but there are different classes which can coex-
ist in the same cell (Kurzchalia et al., 1995). Theseplexes from various cell types suggests that it is im-
portant for LMP1 functions. In this regard, the observa- classes probably have distinct functions and different
protein and glycosphingolipid contents, although theytions made in LMP1-transfected Daudi cells are the most
conclusive. Vimentin was undetectable in the Daudi- have similar physical characteristics (low density and
Triton-insolubility). A distinction has been established be-LMP6 clone and the pool of insoluble LMP1 was much
smaller in Daudi than EBV1 cells (Figs. 4 and 5). These tween caveolar and noncaveolar GSL-domains, but addi-
tional heterogeneity might exist within these two groupsdata are consistent with a report by Leibowitz and Kieff
(1989) concerning LMP1-transfected Daudi cells. In this (Fra et al., 1994; Gorodinsky and Harris, 1995; Schnitzer
et al., 1995). Caveolae are smooth, flask vesicules of 100report, Liebowitz and Kieff had also demonstrated that
LMP1 retains its biological activity in Daudi cells despite nm or less in diameter, appended to the internal face of
the plasma membrane (Rothberg et al., 1992; Schnitzerits minimal association with cytoskeletal elements. LMP1
accumulation in GSL-complexes from Daudi cells is et al., 1995). Caveolar GSL-domains are characterized
not only by their morphology but also by their high con-therefore a strong argument in favor of its contribution
to LMP1 functions. This assumption is further supported tent of caveolin 1—or other members of the caveolin
family—and GM1 ganglioside (Parton et al., 1994;by recent results obtained in our laboratory concerning
a variant form of LMP1 called D1-LMP1. D1-LMP1 results Schnitzer et al., 1995; Scherer et al., 1996). Proteins of
the caveolin family are essential for the morphogenesisfrom alternative splicing of the LMP1 gene and is nor-
mally produced during the EBV lytic cycle. It is truncated of caveolae (Fra et al., 1995). EBV-immortalized B-cells
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Gorodinsky, A., and Harris, D. A. (1995). Glycolipid-anchored proteinsand other lymphoid cells are devoid of caveolae and
in neuroblastoma cells form detergent- resistant complexes withoutcaveolin (Fra et al., 1994; Deckert et al., 1996 and per-
caveolin. J. Cell Biol. 129, 619–627.
sonal data). C15 NPC cells also lack both caveolin 1 Hammarskjold, M. L., and Simurda, M. C. (1992). Epstein–Barr virus
and caveolae as shown by immunocytochemistry and latent membrane protein transactivates the human immunodefi-
electron microscopy (data not shown). The fact that ca- ciency virus type 1 long terminal repeat through induction of NF-
kappa B activity. J. Virol. 66, 6496–6501.veolar GSL-domains are absent in common EBV host
Hanada, K., Nishijima, M., Akamatsu, Y., and Pagano, R. E. (1995). Bothcells suggests that LMP1 associates with noncaveolar
sphingolipids and cholesterol participate in the detergent insolubilityGSL-domains in both lymphoid and epithelial cells.
of alkaline phosphatase, a glycosylphosphatidylinositol-anchored
Therefore, it was not surprising that LMP1 did not colo- protein, in mammalian membranes. J. Biol. Chem. 270, 6254–6260.
calize with caveolin 1 in transfected Hela cells. In future Hu, L. F., Chen, F., Zheng, X., Ernberg, I., Cao, S. L., Christensson, B.,
Klein, G., and Winberg, G. (1993). Clonability and tumorigenicity ofinvestigations, we intend to immunoprecipitate GSL-com-
human epithelial cells expressing the EBV encoded membrane pro-plexes containing LMP1 and to determine what protein
tein LMP1. Oncogene 8, 1575–1583.and glycosphingolipid species they contain. The detec-
Huen, D. S., Henderson, S. A., Croom-Carter, D., and Rowe, M. (1995).
tion of TRAF 3 or other LMP1 binding molecules in these The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates
complexes would contribute to a better understanding of activation of NF-kappa B and cell surface phenotype via two effector
regions in its carboxy-terminal cytoplasmic domain. Oncogene 10,LMP1 functions.
549–560.
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